Meeting
2012 ASCO Annual Meeting
The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).
Authors
Christof Vulsteke
Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
Christof Vulsteke , Diether Lambrechts , Anne-Sophie Dieudonné , Sigrid Hatse , Barbara Brouwers , Thomas Van Brussel , Patrick Neven , Ann Belmans , Patrick Schoffski , Robert Paridaens , Hans Wildiers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1020)
DOI
10.1200/jco.2012.30.15_suppl.1020
Abstract #
1020
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Cyclophosphamide (Cy) pharmacogenetics (PGx) in allogeneic stem cell transplant (SCT) patients (pts) receiving Cy, fludarabine, total body irradiation and post-transplant Cy (FluCyTBI-postCy).
First Author: Jai Narendra Patel
Poster
2013 ASCO Annual Meeting
The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3.
First Author: Christof Vulsteke
Poster
2023 ASCO Breakthrough
Clinical implications of drug-metabolizing genes CYP3A4 and GSTP1 single nucleotide polymorphisms in oral cancer patients undergoing induction chemotherapy.
First Author: Pranab Kumar Sahoo
Poster
2019 Supportive Care in Oncology Symposium
Pharmacogenetic (PGx) guided cancer pain management in an oncology palliative medicine (PM) clinic.
First Author: Jai Narendra Patel